Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. ORCL
2. NVDA
3. SPY
4. USO
5. SRRK
6. CGEM
7. DFTX
8. AZN
9. SATL
10. LYNX

Go back to Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
(NASDAQ: ERNA) Delayed: 4.30 +0.14 (3.37%)
Previous Close $4.16    52 Week High $ 
Open $4.13    52 Week Low $ 
Day High $4.40    P/E N/A 
Day Low $4.13    EPS $ 
Volume 11,518       

(NASDAQ: ERNA) Delayed: 4.30 +0.14 (3.37%)
Previous Close $4.16    52 Week High $ 
Open $4.13    52 Week Low $ 
Day High $4.40    P/E N/A 
Day Low $4.13    EPS $ 
Volume 11,518